By Colin Kellaher
Shares of 2seventy bio took flight Tuesday after the biotechnology company agreed to be acquired by partner Bristol Myers Squibb.
Bristol Myers is paying $5 a share in cash for 2seventy, a 79% premium to Monday's closing price of $2.80 for the Cambridge, Mass., company.
The deal, slated to close in the second quarter, carries a total equity value of about $286 million, or $102 million net of 2seventy's estimated cash.
2seventy shares were recently up 77% to $4.95 in premarket trading.
Princeton, N.J., biopharmaceutical company Bristol Myers and 2seventy are partners on the gene therapy Abecma, which is approved in the U.S. for adults with the blood cancer multiple myeloma.
The companies are jointly developing and commercializing Abecma in the U.S., with Bristol Myers responsible for manufacturing and commercialization outside of the U.S.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
By Colin Kellaher
Shares of 2seventy bio took flight Tuesday after the biotechnology company agreed to be acquired by partner Bristol Myers Squibb.
Bristol Myers is paying $5 a share in cash for 2seventy, a 79% premium to Monday's closing price of $2.80 for the Cambridge, Mass., company.
The deal, slated to close in the second quarter, carries a total equity value of about $286 million, or $102 million net of 2seventy's estimated cash.
2seventy shares were recently up 77% to $4.95 in premarket trading.
Princeton, N.J., biopharmaceutical company Bristol Myers and 2seventy are partners on the gene therapy Abecma, which is approved in the U.S. for adults with the blood cancer multiple myeloma.
The companies are jointly developing and commercializing Abecma in the U.S., with Bristol Myers responsible for manufacturing and commercialization outside of the U.S.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 11, 2025 05:58 ET (09:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。